Try
Dianthus Therapeutics Inc. Common Stock
DNTHUnited States
33 filed reports · 402 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
33 reports · Jun 2018 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 25 | 3,262 | Jun 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 8 | 2,810 | Dec 2018 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 386 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 238 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Mar 9, 2026 | 600 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 261 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 170 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 12, 2025 | 184 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Mar 11, 2025 | 445 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 169 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 148 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 161 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 21, 2024 | 376 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 9, 2023 | 138 | Open |
Financial data
402 concepts · 6,072 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial398 concepts · 5,923 facts · Dec 2016 to Aug 2026
- Net income loss48 · Dec 2016 to Jun 2026
- Operating income loss48 · Dec 2016 to Jun 2026
- Allocated share based compensation expense47 · Dec 2016 to Jun 2026
- Cash and cash equivalents at carrying value47 · Dec 2016 to Jun 2026
- Comprehensive income net of tax47 · Dec 2016 to Jun 2026
- General and administrative expense (US GAAP)47 · Dec 2016 to Jun 2026
- Operating expenses (US GAAP)47 · Dec 2016 to Jun 2026
- Research and development expense47 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents46 · Dec 2016 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets46 · Dec 2016 to Jun 2026
- Net cash provided by used in financing activities46 · Dec 2016 to Jun 2026
- Net cash provided by used in investing activities46 · Dec 2016 to Jun 2026
- Net cash provided by used in operating activities46 · Dec 2016 to Jun 2026
- Profit loss46 · Dec 2016 to Jun 2026
- Share based compensation46 · Dec 2016 to Jun 2026
- Stockholders equity (US GAAP)46 · Dec 2016 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value44 · Dec 2016 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect44 · Dec 2016 to Jun 2026
- Common stock shares issued44 · Dec 2017 to Jun 2026
- Accounts payable current43 · Dec 2017 to Jun 2026
- Accrued liabilities and other liabilities43 · Dec 2017 to Jun 2026
- Additional paid in capital common stock43 · Dec 2017 to Jun 2026
- Assets43 · Dec 2017 to Jun 2026
- Assets current43 · Dec 2017 to Jun 2026
Product4 concepts · 149 facts · Dec 2023 to Jun 2026
- Research and development expense51 · Dec 2023 to Jun 2026
- Clinical operation activities47 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)38 · Dec 2023 to Jun 2026
- Revenue13 · Dec 2023 to Jun 2026
Segments
149 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service11 members · 149 facts
- Other Costs36 · Dec 2023 to Jun 2026
- Personnel And Related Costs26 · Dec 2023 to Jun 2026
- Share Based Compensation Expense14 · Jun 2024 to Jun 2026
- Clinical Operation Activities13 · Dec 2023 to Jun 2026
- Discovery Expenses13 · Dec 2023 to Jun 2026
- License13 · Dec 2023 to Jun 2026
- Share Based Compensation10 · Dec 2023 to Dec 2025
- CMC Activities8 · Dec 2023 to Jun 2026
- Preclinical Study Activity Costs7 · Jun 2024 to Jun 2026
- Preclinical Study Costs5 · Dec 2023 to Dec 2025
- Chemistry Manufacturing And Control Activity Costs4 · Jun 2024 to Sep 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary137 claims from 10 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary126 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes49 claims from 1 reports · Dec 2025
- Risk factors100 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.